Abstracts tagged "Adalimumab and spondylarthropathy"

Abstract Number: 2214 • 2012 ACR/ARHP Annual Meeting
Similar Levels of Disease Activity in Patients with Oligoarticular Vs. Polyarticular Peripheral Spondyloarthritis
Filip Van den Bosch¹, Philip J. Mease², Désirée van der Heijde³, Martin Rudwaleit⁴, Katie Obermeyer⁵ and Aileen L. Pangan⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Endokrinologikum Berlin, Berlin, Germany, ⁵Abbott Laboratories, Abbott Park, IL
Background/Purpose: The ASAS criteria for peripheral spondyloarthritis (SpA) allow for classification of patients with SpA who present with peripheral arthritis, enthesitis and/or dactylitis.1 ABILITY-2, a…
Abstract Number: 570 • 2012 ACR/ARHP Annual Meeting
Randomized Controlled Trial of Adalimumab in Patients with Peripheral Spondyloarthritis
Philip J. Mease¹, Joachim Sieper², Filip Van den Bosch³, Proton Rahman⁴, Katie Obermeyer⁵ and Aileen L. Pangan⁵, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ³Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁵Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) is indicated for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Patients (pts) with peripheral spondyloarthritis (SpA) not previously diagnosed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].